|
Cardiovascular Vulnerability to Particulate Exposure Clinical Trials Information presented on Clinical Trials Search isn't intended to be a substitute for proven healthcare advice, trips or treatment using a real physician. We are not docs. Always confer with your mD on Cardiovascular Vulnerability to Particulate Exposure conditions. Clinical Trials Search.org is a site dedicated to listing clinical research studies in human subjects. Cardiovascular Vulnerability to Particulate Exposure Clinical research trials and Cardiovascular Vulnerability to Particulate Exposure medical trials take place in hundreds of localities across the U.S.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials usually measure the effectiveness of new drugs. The intention of the studies / projects is to resolve certain human health questions. Clinical trials are a popular means for physicians, government agencies, and private sector corporations to detect remedies for all forms of circumstances, like Cardiovascular Vulnerability to Particulate Exposure. Cardiovascular Vulnerability to Particulate Exposure Clinical Trials and other clinical trials allow for volunteers to undergo healthcare treatment options before they are available to the masses. Most times the participants receive treatment for free, and every now and again they are paid for their time. Occasionally there is a cost for a Cardiovascular Vulnerability to Particulate Exposure clinical trial. Subjects typically recieve the finest healthcare available for their Cardiovascular Vulnerability to Particulate Exposure condition. Hazards are a reality, nonetheless, and might include more or frequent mD trips, health risks (potentially life-endangering), and/or the treatment being ineffective. Trials are federally regulated with stern guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "C" Clinical Trials Conditions > Cardiovascular Vulnerability to Particulate Exposure  Cardiovascular Vulnerability to Particulate Exposure
Cardiovascular Vulnerability to Particulate Exposure
For Condition: Lung Disease,Heart Disease
Status: Recruiting
Sponsor(s): National Institute of Environmental Health Sciences (NIEHS) ,
Synopsis: This project is part of a program project directed toward assessing cardiac effects of particulate and other ambient air pollutants. In this project active elderly adults living in the communities of Boston and Steubenville have attended 12 weekly sessions including approximately 40 minutes of Holter monitoring, blood pressure, and oximetry evaluation before, during, and after outdoor exercise. To investigate the relation of air pollution to cardiac and pulmonary rehabilitation, a second portion of this study involves abstraction of blood pressure and symptom data and downloading of available repeated measures telemetry data in two populations. These populations include: 1) 200 outpatients attending 8 to 36 repeated weekly exercise training sessions in a major hospital cardiac rehabilitation unit.
Details: Approximately 60 subjects have participated fully in Boston and Steubenville in the repeated 40 minute measurement of continuous EKG (Holter), blood pressure, and oximetry. In Steubenville we have also measured exhaled nitrogen oxide, an index of pulmonary inflammation. The exposure monitoring has included outdoor particle mass of PM2.5, outdoor gaseous pollutants, and indoor home and personal monitoring to evaluate the indoor contribution of pollution to health effects.
Eligibility:
Study Type: Observational, Natural History, Longitudinal, Defined Population, Prospective Study
Minimum Age/Maximum Age: 50 Years/90 Years
Genders: Both
Protocol Entry Criteria: Participants are 50 to 90 years of age, but almost all are 60 and older. They have been enrolled as volunteers from communities in Mission Park, Boston, and Steubenville. Inclusion criteria includes the ability to walk on level ground. Exclusion criteria includes unstable anginal, and baseline EKG patterns such as left bundle branch block that would make difficult the detection of repolarization abnormalities. Participants live at or near the study center which was located in an office or apartment in the apartment building of the majority of the participants.
Total Enrollment: 200
Location and Contact Information:
Overall Study Official:
DianeGold, Study Director, Harvard School of Public Health
Brigham and Women's Hospital *Recruiting*
Boston, Massachusetts, 02115
United States
Recruiting Diane Gold 617-525-2738
Additional Information:
Study ID Numbers: 9825-CP-003;
Study Start Date: September 1998
Record last reviewed: April 2001
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00013949
Other Heart Disease Studies:
1. Biomarkers of Benzene Exposure in Inner City Residents
2. Development of a Hospital-Based Home Program for the Use of Inhaled Nitric Oxide in the Chronic Management of Severe Cardiopulmonary Diseases
3. A Randomized, Double-Blind, Three-arm, Phase 3b Study Comparing the Safety and efficacy of Interferon gamma-1b with Azatioprine, and Azathioprine Alone in Patients with IPF Receiving Prednisone
4. Role of Genetic Factors in the Development of Lung Disease
5. Study of the Disease Process of Lymphangioleiomyomatosis
Related Studies:
Other Heart Disease Clinical Trials
Other Massachusetts Clinical Trials
Other Boston Clinical Trials
Cardiovascular Vulnerability to Particulate Exposure
|
|
|
|
|
|
|
|
